Pharmacokinetics of Rizatriptan Tablets During and Between Migraine Attacks
Gastric stasis during migraine attacks results in delayed absorption of several orally administered antimigraine agents. This study, as part of a larger trial, was conducted to examine the pharmacokinetics of rizatriptan tablets during and between migraine attacks. Participating patients met IHS cri...
Gespeichert in:
| Veröffentlicht in: | Headache 1999-04, Vol.39 (4), p.264-269 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 269 |
|---|---|
| container_issue | 4 |
| container_start_page | 264 |
| container_title | Headache |
| container_volume | 39 |
| creator | Cutler, Neal R. Jhee, Stanford S. Majumdar, Anup K. McLaughlin, Debra Brucker, Mary Jo Carides, Alexandra D. Kramer, Mark S. Matzura-Wolfe, Deborah Reines, Scott A. Goldberg, Michael R. |
| description | Gastric stasis during migraine attacks results in delayed absorption of several orally administered antimigraine agents. This study, as part of a larger trial, was conducted to examine the pharmacokinetics of rizatriptan tablets during and between migraine attacks. Participating patients met IHS criteria for migraine with or without aura, and suffered between one and eight migraines per month for the previous 6 months. In part 1 of the study, 21 patients were randomized to receive a single 5‐mg tablet of rizatriptan or placebo in the migraine‐free state. In part 2, the same patients were treated during migraine with rizatriptan 5‐mg tablets (n=18) or placebo (n=3). Blood samples were obtained before dosing and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours after dosing. The plasma concentration profile (ie, AUC(0‐∞), Cmax, Tmax) of rizatriptan 5‐mg tablets administered during and between migraine attacks were comparable. The median Tmax for rizatriptan between and during attacks was 1 hour, indicating rapid absorption even during a migraine attack. Rizatriptan 5 mg was well tolerated and 67% of the patients experienced headache relief 2 hours postdose. |
| doi_str_mv | 10.1046/j.1526-4610.1999.3904264.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70859454</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70859454</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3904-cc797142f6e80dd1363ba9081184ffaf57d5e6e21573c59246d0f38e70d01c553</originalsourceid><addsrcrecordid>eNqVkO9rEzEYx4Mork7_BTlExDdXk8uvi--6dm6yqUUmvgxp7slMe72rSco6_3pz9NjeCUIgJPl8v3n4IPSG4CnBTHxYTwmvRMnEcKGUmlKFWSXY9PAETR6enqIJxkSWtWT1CXoR4xrjnFbiOTohXBBaVXSCrpa_TNga2298B8nbWPSu-O7_mBT8LpmuuDGrFlIsFvvgu9vCdE1xBukOoCu--NtgcqyYpWTsJr5Ez5xpI7wa91P049P5zfyyvP528Xk-uy7tMGhprVSSsMoJqHHTECroyihcE1Iz54zjsuEgoCJcUstVxUSDHa1B4gYTyzk9Re-OvbvQ_95DTHrro4W2NR30-6glrrlinGXw_T_BrAETygmuMvrxiNrQxxjA6V3wWxPuNcF6sK7XelCrB7V6sK5H6_qQw6_Hf_arLTSP0VFzBt6OgInWtC6Yzvr4yEkxrIzNj9idb-H-PybQl-ezxXjKLeWxxccEh4cWEzZaSCq5_vn1Qi_FQsorutRL-hdYAaw_</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1560135102</pqid></control><display><type>article</type><title>Pharmacokinetics of Rizatriptan Tablets During and Between Migraine Attacks</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Cutler, Neal R. ; Jhee, Stanford S. ; Majumdar, Anup K. ; McLaughlin, Debra ; Brucker, Mary Jo ; Carides, Alexandra D. ; Kramer, Mark S. ; Matzura-Wolfe, Deborah ; Reines, Scott A. ; Goldberg, Michael R.</creator><creatorcontrib>Cutler, Neal R. ; Jhee, Stanford S. ; Majumdar, Anup K. ; McLaughlin, Debra ; Brucker, Mary Jo ; Carides, Alexandra D. ; Kramer, Mark S. ; Matzura-Wolfe, Deborah ; Reines, Scott A. ; Goldberg, Michael R.</creatorcontrib><description>Gastric stasis during migraine attacks results in delayed absorption of several orally administered antimigraine agents. This study, as part of a larger trial, was conducted to examine the pharmacokinetics of rizatriptan tablets during and between migraine attacks. Participating patients met IHS criteria for migraine with or without aura, and suffered between one and eight migraines per month for the previous 6 months. In part 1 of the study, 21 patients were randomized to receive a single 5‐mg tablet of rizatriptan or placebo in the migraine‐free state. In part 2, the same patients were treated during migraine with rizatriptan 5‐mg tablets (n=18) or placebo (n=3). Blood samples were obtained before dosing and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours after dosing. The plasma concentration profile (ie, AUC(0‐∞), Cmax, Tmax) of rizatriptan 5‐mg tablets administered during and between migraine attacks were comparable. The median Tmax for rizatriptan between and during attacks was 1 hour, indicating rapid absorption even during a migraine attack. Rizatriptan 5 mg was well tolerated and 67% of the patients experienced headache relief 2 hours postdose.</description><identifier>ISSN: 0017-8748</identifier><identifier>EISSN: 1526-4610</identifier><identifier>DOI: 10.1046/j.1526-4610.1999.3904264.x</identifier><identifier>PMID: 15613223</identifier><identifier>CODEN: HEADAE</identifier><language>eng</language><publisher>USA/Oxford, UK: American Association for the Study of Headache/Blackwell Science Ltd</publisher><subject>5-HT1D receptor agonist ; Adolescent ; Adult ; Aged ; Biological and medical sciences ; Cardiovascular system ; Dose-Response Relationship, Drug ; Female ; Humans ; Male ; Medical sciences ; Middle Aged ; migraine ; Migraine Disorders - drug therapy ; pharmacokinetics ; Pharmacology. Drug treatments ; Serotonin Receptor Agonists - blood ; Serotonin Receptor Agonists - pharmacokinetics ; Serotonin Receptor Agonists - therapeutic use ; Time Factors ; Triazoles - blood ; Triazoles - pharmacokinetics ; Triazoles - therapeutic use ; Tryptamines - blood ; Tryptamines - pharmacokinetics ; Tryptamines - therapeutic use ; Vasodilator agents. Cerebral vasodilators</subject><ispartof>Headache, 1999-04, Vol.39 (4), p.264-269</ispartof><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3904-cc797142f6e80dd1363ba9081184ffaf57d5e6e21573c59246d0f38e70d01c553</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1046%2Fj.1526-4610.1999.3904264.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1046%2Fj.1526-4610.1999.3904264.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1761761$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15613223$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cutler, Neal R.</creatorcontrib><creatorcontrib>Jhee, Stanford S.</creatorcontrib><creatorcontrib>Majumdar, Anup K.</creatorcontrib><creatorcontrib>McLaughlin, Debra</creatorcontrib><creatorcontrib>Brucker, Mary Jo</creatorcontrib><creatorcontrib>Carides, Alexandra D.</creatorcontrib><creatorcontrib>Kramer, Mark S.</creatorcontrib><creatorcontrib>Matzura-Wolfe, Deborah</creatorcontrib><creatorcontrib>Reines, Scott A.</creatorcontrib><creatorcontrib>Goldberg, Michael R.</creatorcontrib><title>Pharmacokinetics of Rizatriptan Tablets During and Between Migraine Attacks</title><title>Headache</title><addtitle>Headache</addtitle><description>Gastric stasis during migraine attacks results in delayed absorption of several orally administered antimigraine agents. This study, as part of a larger trial, was conducted to examine the pharmacokinetics of rizatriptan tablets during and between migraine attacks. Participating patients met IHS criteria for migraine with or without aura, and suffered between one and eight migraines per month for the previous 6 months. In part 1 of the study, 21 patients were randomized to receive a single 5‐mg tablet of rizatriptan or placebo in the migraine‐free state. In part 2, the same patients were treated during migraine with rizatriptan 5‐mg tablets (n=18) or placebo (n=3). Blood samples were obtained before dosing and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours after dosing. The plasma concentration profile (ie, AUC(0‐∞), Cmax, Tmax) of rizatriptan 5‐mg tablets administered during and between migraine attacks were comparable. The median Tmax for rizatriptan between and during attacks was 1 hour, indicating rapid absorption even during a migraine attack. Rizatriptan 5 mg was well tolerated and 67% of the patients experienced headache relief 2 hours postdose.</description><subject>5-HT1D receptor agonist</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Cardiovascular system</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>migraine</subject><subject>Migraine Disorders - drug therapy</subject><subject>pharmacokinetics</subject><subject>Pharmacology. Drug treatments</subject><subject>Serotonin Receptor Agonists - blood</subject><subject>Serotonin Receptor Agonists - pharmacokinetics</subject><subject>Serotonin Receptor Agonists - therapeutic use</subject><subject>Time Factors</subject><subject>Triazoles - blood</subject><subject>Triazoles - pharmacokinetics</subject><subject>Triazoles - therapeutic use</subject><subject>Tryptamines - blood</subject><subject>Tryptamines - pharmacokinetics</subject><subject>Tryptamines - therapeutic use</subject><subject>Vasodilator agents. Cerebral vasodilators</subject><issn>0017-8748</issn><issn>1526-4610</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkO9rEzEYx4Mork7_BTlExDdXk8uvi--6dm6yqUUmvgxp7slMe72rSco6_3pz9NjeCUIgJPl8v3n4IPSG4CnBTHxYTwmvRMnEcKGUmlKFWSXY9PAETR6enqIJxkSWtWT1CXoR4xrjnFbiOTohXBBaVXSCrpa_TNga2298B8nbWPSu-O7_mBT8LpmuuDGrFlIsFvvgu9vCdE1xBukOoCu--NtgcqyYpWTsJr5Ez5xpI7wa91P049P5zfyyvP528Xk-uy7tMGhprVSSsMoJqHHTECroyihcE1Iz54zjsuEgoCJcUstVxUSDHa1B4gYTyzk9Re-OvbvQ_95DTHrro4W2NR30-6glrrlinGXw_T_BrAETygmuMvrxiNrQxxjA6V3wWxPuNcF6sK7XelCrB7V6sK5H6_qQw6_Hf_arLTSP0VFzBt6OgInWtC6Yzvr4yEkxrIzNj9idb-H-PybQl-ezxXjKLeWxxccEh4cWEzZaSCq5_vn1Qi_FQsorutRL-hdYAaw_</recordid><startdate>199904</startdate><enddate>199904</enddate><creator>Cutler, Neal R.</creator><creator>Jhee, Stanford S.</creator><creator>Majumdar, Anup K.</creator><creator>McLaughlin, Debra</creator><creator>Brucker, Mary Jo</creator><creator>Carides, Alexandra D.</creator><creator>Kramer, Mark S.</creator><creator>Matzura-Wolfe, Deborah</creator><creator>Reines, Scott A.</creator><creator>Goldberg, Michael R.</creator><general>American Association for the Study of Headache/Blackwell Science Ltd</general><general>Blackwell</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>199904</creationdate><title>Pharmacokinetics of Rizatriptan Tablets During and Between Migraine Attacks</title><author>Cutler, Neal R. ; Jhee, Stanford S. ; Majumdar, Anup K. ; McLaughlin, Debra ; Brucker, Mary Jo ; Carides, Alexandra D. ; Kramer, Mark S. ; Matzura-Wolfe, Deborah ; Reines, Scott A. ; Goldberg, Michael R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3904-cc797142f6e80dd1363ba9081184ffaf57d5e6e21573c59246d0f38e70d01c553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>5-HT1D receptor agonist</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Cardiovascular system</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>migraine</topic><topic>Migraine Disorders - drug therapy</topic><topic>pharmacokinetics</topic><topic>Pharmacology. Drug treatments</topic><topic>Serotonin Receptor Agonists - blood</topic><topic>Serotonin Receptor Agonists - pharmacokinetics</topic><topic>Serotonin Receptor Agonists - therapeutic use</topic><topic>Time Factors</topic><topic>Triazoles - blood</topic><topic>Triazoles - pharmacokinetics</topic><topic>Triazoles - therapeutic use</topic><topic>Tryptamines - blood</topic><topic>Tryptamines - pharmacokinetics</topic><topic>Tryptamines - therapeutic use</topic><topic>Vasodilator agents. Cerebral vasodilators</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cutler, Neal R.</creatorcontrib><creatorcontrib>Jhee, Stanford S.</creatorcontrib><creatorcontrib>Majumdar, Anup K.</creatorcontrib><creatorcontrib>McLaughlin, Debra</creatorcontrib><creatorcontrib>Brucker, Mary Jo</creatorcontrib><creatorcontrib>Carides, Alexandra D.</creatorcontrib><creatorcontrib>Kramer, Mark S.</creatorcontrib><creatorcontrib>Matzura-Wolfe, Deborah</creatorcontrib><creatorcontrib>Reines, Scott A.</creatorcontrib><creatorcontrib>Goldberg, Michael R.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Headache</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cutler, Neal R.</au><au>Jhee, Stanford S.</au><au>Majumdar, Anup K.</au><au>McLaughlin, Debra</au><au>Brucker, Mary Jo</au><au>Carides, Alexandra D.</au><au>Kramer, Mark S.</au><au>Matzura-Wolfe, Deborah</au><au>Reines, Scott A.</au><au>Goldberg, Michael R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacokinetics of Rizatriptan Tablets During and Between Migraine Attacks</atitle><jtitle>Headache</jtitle><addtitle>Headache</addtitle><date>1999-04</date><risdate>1999</risdate><volume>39</volume><issue>4</issue><spage>264</spage><epage>269</epage><pages>264-269</pages><issn>0017-8748</issn><eissn>1526-4610</eissn><coden>HEADAE</coden><abstract>Gastric stasis during migraine attacks results in delayed absorption of several orally administered antimigraine agents. This study, as part of a larger trial, was conducted to examine the pharmacokinetics of rizatriptan tablets during and between migraine attacks. Participating patients met IHS criteria for migraine with or without aura, and suffered between one and eight migraines per month for the previous 6 months. In part 1 of the study, 21 patients were randomized to receive a single 5‐mg tablet of rizatriptan or placebo in the migraine‐free state. In part 2, the same patients were treated during migraine with rizatriptan 5‐mg tablets (n=18) or placebo (n=3). Blood samples were obtained before dosing and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours after dosing. The plasma concentration profile (ie, AUC(0‐∞), Cmax, Tmax) of rizatriptan 5‐mg tablets administered during and between migraine attacks were comparable. The median Tmax for rizatriptan between and during attacks was 1 hour, indicating rapid absorption even during a migraine attack. Rizatriptan 5 mg was well tolerated and 67% of the patients experienced headache relief 2 hours postdose.</abstract><cop>USA/Oxford, UK</cop><pub>American Association for the Study of Headache/Blackwell Science Ltd</pub><pmid>15613223</pmid><doi>10.1046/j.1526-4610.1999.3904264.x</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0017-8748 |
| ispartof | Headache, 1999-04, Vol.39 (4), p.264-269 |
| issn | 0017-8748 1526-4610 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70859454 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | 5-HT1D receptor agonist Adolescent Adult Aged Biological and medical sciences Cardiovascular system Dose-Response Relationship, Drug Female Humans Male Medical sciences Middle Aged migraine Migraine Disorders - drug therapy pharmacokinetics Pharmacology. Drug treatments Serotonin Receptor Agonists - blood Serotonin Receptor Agonists - pharmacokinetics Serotonin Receptor Agonists - therapeutic use Time Factors Triazoles - blood Triazoles - pharmacokinetics Triazoles - therapeutic use Tryptamines - blood Tryptamines - pharmacokinetics Tryptamines - therapeutic use Vasodilator agents. Cerebral vasodilators |
| title | Pharmacokinetics of Rizatriptan Tablets During and Between Migraine Attacks |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T08%3A12%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacokinetics%20of%20Rizatriptan%20Tablets%20During%20and%20Between%20Migraine%20Attacks&rft.jtitle=Headache&rft.au=Cutler,%20Neal%20R.&rft.date=1999-04&rft.volume=39&rft.issue=4&rft.spage=264&rft.epage=269&rft.pages=264-269&rft.issn=0017-8748&rft.eissn=1526-4610&rft.coden=HEADAE&rft_id=info:doi/10.1046/j.1526-4610.1999.3904264.x&rft_dat=%3Cproquest_cross%3E70859454%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1560135102&rft_id=info:pmid/15613223&rfr_iscdi=true |